

## Correction to “Molecular Aspects of Antitumor Effects of a New Platinum(IV) Drug”

The above article [Kasparkova J, Novakova O, Vrana O, Intini F, Natile G, and Brabec V (2006) *Mol Pharmacol* **70**:1708–1719] describes results obtained exclusively by the authors. This article also describes some modifications of DNA by *cis*-[PtCl<sub>2</sub>(NH<sub>3</sub>)(1-adamantylamine)]. The platinum complex used in this study was from two resources. One sample was synthesized and characterized in the way described under *Materials and Methods*; the other sample of this complex was obtained from PLIVA-Lachema a.s. (Brno, Czech Republic), which uses the abbreviation LA-9 for this complex and LA-12 for its tetravalent analog *cis,trans,cis*-[PtCl<sub>2</sub>(CH<sub>3</sub>COO)<sub>2</sub>(NH<sub>3</sub>)(1-adamantylamine)]. The results obtained with *cis*-[PtCl<sub>2</sub>(NH<sub>3</sub>)(1-adamantylamine)] from both resources were identical in regard to content, significance, and the extent of the interpretation and conclusions based on the interpretation mentioned in this article. The fact that the results discussed in this article were also obtained with the complex *cis*-[PtCl<sub>2</sub>(NH<sub>3</sub>)(1-adamantylamine)] (LA-9) obtained from PLIVA-Lachema a.s. was omitted.

The authors regret this omission and apologize for any confusion or inconvenience it may have caused.